Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration

Abstract Background The anti-vascular endothelial growth factor (anti-VEGF) injection interval influences treatment burden and compliance in neovascular age-related macular degeneration (nAMD). This real-world study investigates visual acuity (VA), injection-interval extension, central macular thick...

Full description

Bibliographic Details
Main Authors: Joseph M. Coney, Ryan Zubricky, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou, Thomas P. Hull, Shawn A. Lewis, David G. Miller, Michael A. Novak, Scott D. Pendergast, Hang Pham, Sean M. Platt, Llewelyn J. Rao, Jerome P. Schartman, Lawrence J. Singerman, Richard Donkor, Margaret Fink, Jasmyne McCoy, Helene Karcher
Format: Article
Language:English
Published: BMC 2023-02-01
Series:International Journal of Retina and Vitreous
Subjects:
Anti-VEGF
Brolucizumab
Beovu
Injection intervals
nAMD
Neovascular age-related macular degeneration
Online Access:https://doi.org/10.1186/s40942-023-00445-0

Internet

https://doi.org/10.1186/s40942-023-00445-0

Similar Items